Health Canada Approves PrSYMDEKO (tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of Cystic Fibrosis Genetics Investing
Genentech Announces New OCREVUS (Ocrelizumab) Data on Long-Term Disability Benefits Genetics Investing
Seattle Genetics Announces First Patient Dosed in Phase 2 Trial of Tisotumab Vedotin Genetics Investing
Cutera Announces Expansion of FDA Indications for the truSculpt® Body Contouring System Longevity Investing
Cynata Reports Positive Six-Month Data from Cohort A in Phase 1 Trial of CYP-001 in GvHD Genetics Investing
Precipio Strengthens Patent Portfolio with Expanded Kit Claims for its Liquid Biopsy Enabling DNA Mutation Enrichment Technology Medical Device Investing